Literature DB >> 2013927

Concordance for dyslipidemic hypertension in male twins.

J V Selby1, B Newman, J Quiroga, J C Christian, M A Austin, R R Fabsitz.   

Abstract

Sixty cases of dyslipidemic hypertension were identified in the 1028 middle-aged, white, male twin participants in the first examination of the National Heart, Lung, and Blood Institute Twin Study (1969 to 1973). The prevalence of dyslipidemic hypertension was similar by zygosity but proband concordance was three times greater in monozygotic than dizygotic twins (0.44 [seven concordant and 18 discordant pairs] vs 0.14 [two concordant and 24 discordant pairs]), suggesting a genetic effect on the condition. Low high-density lipoprotein cholesterol level was the most common lipid abnormality in concordant pairs. Mortality from ischemic heart disease was significantly higher in individuals with dyslipidemic hypertension. Obesity and glucose intolerance were closely associated with the syndrome. Moreover, within the 18 discordant monozygotic twin pairs, the twins with dyslipidemic hypertension had gained significantly more weight as adults and were significantly heavier than their unaffected cotwins. Thus, although genetic factors may influence development of dyslipidemic hypertension, nongenetic, potentially modifiable aspects of obesity are also closely related to expression of this clinically important syndrome.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2013927

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  13 in total

1.  Blood pressure reactivity predicts somatic reactivity to stress in daily life.

Authors:  Clayton J Hilmert; Scott Ode; Desiree J Zielke; Michael D Robinson
Journal:  J Behav Med       Date:  2010-03-05

2.  Evaluation of Lipid Profile and Apolipoproteins in Essential Hypertensive Patients.

Authors:  Parsuram Nayak; Suchismita Panda; Pravat Kumar Thatoi; Roma Rattan; Srikrushna Mohapatra; Pramila Kumari Mishra
Journal:  J Clin Diagn Res       Date:  2016-10-01

3.  Upstream stimulatory factor 1 associated with familial combined hyperlipidemia, LDL cholesterol, and triglycerides.

Authors:  Hilary Coon; Yuanpei Xin; Paul N Hopkins; Richard M Cawthon; Sandra J Hasstedt; Steven C Hunt
Journal:  Hum Genet       Date:  2005-06-16       Impact factor: 4.132

4.  Clustering of hypertension, diabetes, and obesity in adult male twins: same genes or same environments?

Authors:  D Carmelli; L R Cardon; R Fabsitz
Journal:  Am J Hum Genet       Date:  1994-09       Impact factor: 11.025

5.  Taking a family history of hypertension: is there patient care benefit?

Authors:  Joel Handler
Journal:  J Clin Hypertens (Greenwich)       Date:  2010-12-17       Impact factor: 3.738

6.  Impaired fatty acid metabolism in familial combined hyperlipidemia. A mechanism associating hepatic apolipoprotein B overproduction and insulin resistance.

Authors:  M Castro Cabezas; T W de Bruin; H W de Valk; C C Shoulders; H Jansen; D Willem Erkelens
Journal:  J Clin Invest       Date:  1993-07       Impact factor: 14.808

7.  Disruptive insights in psychiatry: transforming a clinical discipline.

Authors:  Thomas R Insel
Journal:  J Clin Invest       Date:  2009-04-01       Impact factor: 14.808

8.  Serum lipids and associated factors of dyslipidemia in the adult population in Shenzhen.

Authors:  Wen-Qing Ni; Xiao-Li Liu; Zhi-Peng Zhuo; Xue-Li Yuan; Jin-Ping Song; Hong-Shan Chi; Jian Xu
Journal:  Lipids Health Dis       Date:  2015-07-14       Impact factor: 3.876

Review 9.  Are there genetic paths common to obesity, cardiovascular disease outcomes, and cardiovascular risk factors?

Authors:  Tuomo Rankinen; Mark A Sarzynski; Sujoy Ghosh; Claude Bouchard
Journal:  Circ Res       Date:  2015-02-27       Impact factor: 17.367

10.  Several lipid-related gene polymorphisms interact with overweight/obesity to modulate blood pressure levels.

Authors:  Rui-Xing Yin; Dong-Feng Wu; Lynn Htet Htet Aung; Ting-Ting Yan; Xiao-Li Cao; Xing-Jiang Long; Lin Miao; Wan-Ying Liu; Lin Zhang; Meng Li
Journal:  Int J Mol Sci       Date:  2012-09-24       Impact factor: 6.208

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.